Immune to Cancer: The CRI Blog
-
Remembering Renowned Immunology Pioneer Georg Klein
The longtime member of CRI’s Scientific Advisory Council sought to save lives through research and education.
-
ASH 2016: Tackling Blood Cancers with Immunotherapy
The largest meeting focused on blood cancers begins December 3 in San Diego.
-
CRI, LRF Team Up to Improve How Doctors Assess Lymphoma Patients Treated with Immunotherapy
LYRIC might provide a better way to gauge immunotherapy responses in lymphoma patients. Clinical trials are essential…
-
Cancer Research Institute Opens Nasdaq Market in Ceremony Celebrating Cancer Immunotherapy
If you watch the stock markets closely, you may have seen our CEO and director of scientific…
-
Cancer Research Institute Wins $1 Million from Revlon for Women’s Cancers
We took first place in the second annual Revlon LOVE IS ON Million Dollar Challenge.
-
CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role
First-line lung cancer immunotherapy approval results from century-long effort to harness the immune system to fight cancer.
-
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.